stoxline Quote Chart Rank Option Currency Glossary
  
Comera Life Sciences Holdings, Inc. (CMRA)
0.034  0 (0%)    03-28 13:12
Open: 0.0372
High: 0.04
Volume: 11,518
  
Pre. Close: 0.034
Low: 0.034
Market Cap: 1(M)
Technical analysis
2024-03-28 4:50:30 PM
Short term     
Mid term     
Targets 6-month :  0.05 1-year :  0.07
Resists First :  0.05 Second :  0.05
Pivot price 0.04
Supports First :  0.03 Second :  0.02
MAs MA(5) :  0.03 MA(20) :  0.04
MA(100) :  0.08 MA(250) :  0.35
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  1.2 D(3) :  2.5
RSI RSI(14): 41.4
52-week High :  0.95 Low :  0.02
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CMRA ] has closed above bottom band by 22.5%. Bollinger Bands are 58.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 74 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.04 - 0.04 0.04 - 0.04
Low: 0.03 - 0.03 0.03 - 0.03
Close: 0.03 - 0.03 0.03 - 0.03
Company Description

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Headline News

Wed, 31 Jan 2024
Comera Life Sciences Faces Partnership and Acquisition Setbacks - TipRanks.com - TipRanks

Thu, 04 Jan 2024
Comera Life Sciences Announces Bridge Financing and Exercise of Take Private Option - GlobeNewswire

Wed, 06 Dec 2023
Comera Life Sciences Announces Process Exploring Strategic Alternatives - Yahoo Finance

Mon, 13 Nov 2023
Comera Life Sciences Appoints Dorothy Clarke to Board of Directors - BioSpace

Thu, 11 May 2023
Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights - GlobeNewswire

Wed, 09 Nov 2022
Comera Life Sciences Appoints Janice Marie McCourt as Chief Business Officer - citybiz

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out -3 (M)
Shares Float 0 (M)
Held by Insiders 3.074e+007 (%)
Held by Institutions 8.54e+006 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.22
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 582.4 %
Return on Equity (ttm) -119.4 %
Qtrly Rev. Growth 629 %
Gross Profit (p.s.) 95.58
Sales Per Share 187.12
EBITDA (p.s.) 352258
Qtrly Earnings Growth -7.55e+006 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value -0.16
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 281550
Forward Dividend 27930
Dividend Yield 828088000%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android